EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sulfonamide‐Bearing Pyrazolone Derivatives as Multitarget Therapeutic Agents: Design, Synthesis, Characterization, Biological Evaluation, In Silico ADME /T Profiling and Molecular Docking Study

Nebih Lolak iD, Suleyman Akocak, Meryem Topal, Ümit Muhammet Koçyiğit, Mesut Işık iD, Cüneyt Türkeş, Fevzi Topal, Mustafa Durgun, Şükrü Beydemir

Pharmacology Research & Perspectives · 2025

DOI: 10.1002/prp2.70088 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2025. Verfasst von Nebih Lolak und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Adıyaman University, Adıyaman, Turkey. Hauptthemen laut MEDLINE: Sulfonamides, Carbonic Anhydrase Inhibitors, Cholinesterase Inhibitors, Pyrazolones. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Adıyaman University, Anadolu University, Adiyaman Üniversitesi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The research and design of new inhibitors for the treatment of diseases such as Alzheimer's disease and glaucoma through inhibition of cholinesterases (ChEs; acetylcholinesterase, AChE and butyrylcholinesterase, BChE) and carbonic anhydrase enzymes are among the important targets. Here, a series of novel sulfonamide‐bearing pyrazolone derivatives ( 1a–f and 2a–f ) were successfully synthesized and characterized by using spectroscopic and analytical methods. The inhibitory activities of these newly synthesized compounds were evaluated both in vitro and in silico for their effect on carbonic anhydrases ( h CA I and h CA II isoenzymes) and ChEs. The in vitro studies showed that these novel compounds demonstrated potential inhibitory activity, with K I values covering the following ranges: 18.03 ± 2.86–75.54 ± 4.91 nM for h CA I, 24.84 ± 1.57–85.42 ± 6.60 nM for h CA II, 7.45 ± 0.98–16.04 ± 1.60 nM for AChE, and 34.78 ± 5.88–135.70 ± 17.39 nM for BChE. Additionally, many of these compounds showed promising inhibitory activity, and some showed higher potency than reference compounds. While the in silico studies have also identified the potential binding positions of these compounds, using the crystal structures of h CA I, II, AChE and BChE receptors. The varying affinities demonstrated by these designed compounds for ChEs and h CA isoenzymes show that these compounds could hold promise as potential alternative agents for selectively inhibiting ChEs and h CAs in the treatment of diseases such as Alzheimer's disease and glaucoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SulfonamidesCarbonic Anhydrase InhibitorsCholinesterase InhibitorsPyrazolonesMolecular Docking SimulationHumansDrug DesignButyrylcholinesteraseAcetylcholinesteraseStructure-Activity RelationshipAlzheimer DiseaseCarbonic Anhydrase IIAnimalsCarbonic Anhydrase I

Stichwörter der Autor:innen

carbonic anhydrase inhibitorscholinesterases inhibitorsglaucomamolecular dockingsulfonamide‐bearing pyrazolones

Substanzen

SulfonamidesCarbonic Anhydrase InhibitorsCholinesterase InhibitorsPyrazolonesButyrylcholinesteraseAcetylcholinesteraseCarbonic Anhydrase IICarbonic Anhydrase I

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Adıyaman University, Adıyaman, Turkey.
  • Vocational School of Health Services, Gümüşhane University, Gümüşhane, Turkey.
  • Department of Biochemistry, Faculty of Pharmacy, Sivas Cumhuriyet University, Sivas, Turkey.
  • Department of Bioengineering, Faculty of Engineering, Bilecik Şeyh Edebali University, Bilecik, Turkey.
  • Department of Biochemistry, Faculty of Pharmacy, Erzincan Binali Yıldırım University, Erzincan, Turkey.
  • Department of Food Engineering, Faculty of Engineering and Natural Sciences, Gümüşhane University, Gümüşhane, Turkey.

ORCID-Profile: Nebih Lolak, Mesut Işık

Förderung

  • Adıyaman University
  • Anadolu University
  • Adiyaman Üniversitesi
  • Anadolu Üniversitesi

Zitieren

APA

Lolak, N., Akocak, S., Topal, M., Koçyiğit, Ü. M., Işık, M., Türkeş, C., Topal, F., Durgun, M., & Beydemir, Ş. (2025). Sulfonamide‐Bearing Pyrazolone Derivatives as Multitarget Therapeutic Agents: Design, Synthesis, Characterization, Biological Evaluation, In Silico ADME /T Profiling and Molecular Docking Study. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70088

Vancouver

Lolak N, Akocak S, Topal M, Koçyiğit ÜM, Işık M, Türkeş C, et al. Sulfonamide‐Bearing Pyrazolone Derivatives as Multitarget Therapeutic Agents: Design, Synthesis, Characterization, Biological Evaluation, In Silico ADME /T Profiling and Molecular Docking Study. Pharmacology Research & Perspectives. 2025. doi:10.1002/prp2.70088

BibTeX
@article{Lolak2025,
  author = {Lolak, Nebih and Akocak, Suleyman and Topal, Meryem and Koçyiğit, Ümit Muhammet and Işık, Mesut and Türkeş, Cüneyt and Topal, Fevzi and Durgun, Mustafa and Beydemir, Şükrü},
  title = {Sulfonamide‐Bearing Pyrazolone Derivatives as Multitarget Therapeutic Agents: Design, Synthesis, Characterization, Biological Evaluation, In Silico ADME /T Profiling and Molecular Docking Study},
  journal = {Pharmacology Research & Perspectives},
  year = {2025},
  doi = {10.1002/prp2.70088}
}
Kostenlos starten →